Evaluation and comparison of side effects of fingolimod in Tabriz

Abstract

Multiple sclerosis (MS) is a chronic disease of the central nervous system characterized by loss of motor and sensory function, which is caused by artificial inflammation and loss of myelin Treatment for MS includes alleviating the disease with immunosuppressives and managing symptoms. In this research, Fingolimod with two brands of Fingolid (Osweh Pharmaceutical Factory) and Marella (Novartis Pharmaceutical Factory) was studied. Fingolimod is a new oral drug used to treat recurrent multiple sclerosis that is often taken once a day. It acts as a sphingosine 1-phosphate receptor antagonist. for Marella and Fingolid; in 0.5 mg capsules; the active substance is fingolimod hydrochloride and inactive substances mannitol, magnesium stearate, gelatin, titanium dioxide, yellow iron oxide. purpose: Evaluation and comparison of side effects of Fingolide and Marella in MS patients in Tabriz. Materials and methods: The study was descriptive-analytical. Data were collected using a questionnaire from patients suffering from MS. A total of 83 patients were studied who used two brands of Fingolide and Marella. Of these, 11 people refused to cooperate and 2 others left the study. Among the consumers, which remained in the total of 70 -, 20 and 50 were consuming Marella and Fingolid respectively. Results: In this study, the statistical population included 60% women and 40% men. The average age of all patients was 34.7. Most patients had the extinguishing and recurrent type of disease. Discussion: In general, these two brands of drugs are not different and the difference in the incidence of side effects might be due to a special mental state that exists in consumers. Also, some side effects might be due to underlying diseases or the interactions between Fingolimod and other drugs.